Caliway Biopharmaceuticals (6919) Q1 2026 earnings summary

Executive summary

• Focused on new drug development for aesthetic medicine and chronic inflammation, with shares listed on TWSE since October 2024.

• Consolidated financials reviewed for Q1 2026 and Q1 2025, with a qualified conclusion due to unreviewed non-significant subsidiaries.

• Main revenue source is health food sales; operates as a single segment.

Financial highlights

• Q1 2026 operating revenue was $2 thousand, down from $50 thousand in Q1 2025.

• Net loss for Q1 2026 was $107,754 thousand, improved from $175,565 thousand in Q1 2025.

• Basic loss per share was $0.07 in Q1 2026, compared to $0.11 in Q1 2025.

• Cash and cash equivalents at March 31, 2026 were $2,539,089 thousand, down from $9,297,482 thousand at March 31, 2025.

• Total assets at March 31, 2026 were $9,536,630 thousand, with equity of $9,362,838 thousand.

Outlook and guidance

• Evaluating the impact of IFRS 18, which will be adopted in Taiwan in 2028; no significant impact expected from other new standards.